Market Cap | 1.17M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -177.82k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -13.00% |
Sales | 66.07k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -10.00% |
Dividend | N/A | Price/Book | EPS next 5Y | - | 52W High Chg | -64.00% | |
Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 2.92B | 52W Low Chg | 100.00% |
Insider Own | 0.69% | ROA | -398.29% | Shares Float | 2.90B | Beta | 3.00 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00040 |
Gross Margin | 64.31% | Profit Margin | -269.15% | Avg. Volume | 13,802,459 | Target Price | - |
Oper. Margin | -47.83% | Earnings Date | - | Volume | 1,001,999 | Change | -20.00% |
Neutra Corp. researches, develops, and provides hemp-derived products in the nutraceutical space in the United States. The company sells hemp-derived products, including products containing delta-8-THC and other cannabinoids, CBD sports creams, and other products. Neutra Corp. was incorporated in 2011 and is based in Houston, Texas.